Here are the 424B prospectus supplements from Northwest Biothrputcs Inc (NWBO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NWBO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NWBO filings page.
Northwest Biotherapeutics, Inc. is registering up to 40,325,000 shares of common stock in connection with a $4.9 million convertible promissory note and related warrants issued on July 29, 2026. This includes 30,625,000 reserve shares assumed at $0.16 per share to satisfy principal and any accrued amounts on the Note, and 9,700,000 shares issuable upon exercise of warrants at $0.205 per share.
The company estimates net proceeds of $4,655,000 after original issue discount and expenses, to be used for general corporate purposes, including working capital, UK production facilities, R&D, regulatory and clinical trial costs, and potential technology acquisitions. Shares of common stock outstanding would be 1,733,922,187 after this offering. As of March 31, 2026, net tangible book value was $(90.7) million, or $(0.06) per share; assuming an average offering price of $0.171, pro forma net tangible book value would be $(84.1) million, or $(0.05) per share, implying dilution of $0.221 per share to new investors. The company emphasizes that investing in its common stock involves a high degree of risk.
Northwest Biotherapeutics, Inc. is registering 21,739,130 shares of common stock at an offering price of $0.23 per share in connection with a $5,000,000 convertible promissory note financing with YA II PN, Ltd. The company expects net proceeds of approximately $4,750,000 after an original issue discount and expenses. These shares are reserved to repay principal and any accrued amounts on the 12‑month, zero‑interest Note, which carries a 5% original issue discount and is convertible, at the holder’s option, at a small discount to the then‑prevailing market price, subject to monthly conversion limits.
Following this offering, the company estimates it will have 1,562,421,212 shares of common stock outstanding. Net proceeds are earmarked for general corporate purposes, including working capital, capital expenditures such as UK production facilities, research and development, regulatory affairs, clinical trials, and potential technology acquisitions and investments.